Fund 13F filing

JPMorgan Chase cut $39.5M of Apogee Therapeutics, Inc. (APGE) stock

SEC Form 13F · Filed Aug 12, 2026

JPMorgan Chase cut $39.5M of Apogee Therapeutics, Inc. (APGE) stock in the quarter ending Jun 30, 2026, per a 13F filed Aug 12, 2026.

A 13F shows holdings at quarter end, so the exact trade dates are not disclosed.

Sold

Apogee Therapeutics, Inc.

Value

$39.5M

More APGE insider and Congress trades

Share this trade

From a public SEC Form 13F, linked above. Not investment advice, and not a recommendation to buy or sell.